Coherus Oncology Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio5.589.47
Forward P/E16.86
P/S Ratio0.601.443.683.752.63
P/B Ratio-1.21-1.92-5.6612.544.46
Price/Tangible Book13.024.51
Price/FCF8.52
Price/OCF8.12
Enterprise Value Ratios
EV/Revenue1.352.794.603.602.45
EV/EBITDA7.32
EV/EBIT7.46
EV/FCF7.93
Profitability & Returns
Return on Equity (ROE)-1.52%0.68%
Return on Assets (ROA)-0.11%-0.22%-0.28%-0.22%0.16%
Return on Invested Capital (ROIC)-0.90%-1.20%-2.05%-2.06%1.11%
Return on Capital Employed (ROCE)-0.57%-0.65%-0.75%-0.51%0.23%
Leverage & Solvency Ratios
Debt/Equity-2.26-2.49-3.504.291.48
Debt/EBITDA2.57
Debt/FCF2.84
Liquidity Ratios
Current Ratio1.211.432.753.645.27
Quick Ratio0.881.142.173.274.79
Efficiency Ratios
Asset Turnover0.490.460.360.430.76
Inventory Turnover1.773.141.831.411.39
Yield & Distribution Ratios
Earnings Yield0.18%-0.64%-0.38%-0.23%0.11%
FCF Yield-0.13%-0.47%-0.31%-0.03%0.12%
Buyback Yield-0.22%-0.21%-0.03%0.10%-0.14%